Despite significant clinical successes, advanced cell and gene therapies face scaling hurdles that limit patient access and commercial viability. Biopharmaceutical developers are struggling with high batch costs and fragmented global reimbursement pathways.
Manufacturing Cost Pressures
Autologous gene therapies, which utilize a patient’s own modified cells, cost upwards of $300,000 per unit to produce. The industry is attempting to transition to allogeneic, off-the-shelf therapies, but immune rejection challenges continue to delay Phase III trials.
Payer Model Adaptation
Traditional health insurance structures remain ill-equipped for single-dose treatments with high upfront prices. Payers and drug developers are negotiating multi-year, outcome-based installment plans to distribute cost risks across extended treatment timelines.